A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

被引：0

作者：

Sara M. Balch

Ines Vaz-Luis

Tianyu Li

Nabihah Tayob

Esha Jain

Karla Helvie

Jorge E. Buendia-Buendia

Erin Shannon

Steven J. Isakoff

Nadine M. Tung

Ian E. Krop

Nancy U. Lin

Nikhil Wagle

Rachel A. Freedman

机构：

[1] The Broad Institute of MIT and Harvard,Department of Data Sciences

[2] Department of Medical Oncology,undefined

[3] Dana-Farber Cancer Institute,undefined

[4] Institut Gustave Roussy,undefined

[5] Unit INSERM 981,undefined

[6] Dana-Farber Cancer Institute,undefined

[7] Massachusetts General Hospital,undefined

[8] Harvard Medical School,undefined

[9] Beth Israel Deaconess Medical Center,undefined

[10] Cellarity,undefined

[11] Inc.,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 189卷

关键词：

HER2+ breast cancer; Trastuzumab; Pertuzumab; Eribulin mesylate;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：411 / 423

页数：12